The efficacy, safety, and persistence of vedolizumab versus adalimumab in patients with inflammatory bowel disease: a systematic review and meta-analysis
Inflammopharmacology · 2025
DOI: 10.1007/s10787-025-01710-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Zhixin Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, 530007, Guangxi, People's Republic of China. Hauptthemen laut MEDLINE: Adalimumab, Antibodies, Monoclonal, Humanized, Inflammatory Bowel Diseases, Gastrointestinal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: This systematic review and meta-analysis compared the efficacy, safety, and treatment persistence of vedolizumab and adalimumab in patients with inflammatory bowel disease (IBD). METHODS: Through a comprehensive search of three databases up to September 2024, we calculated pooled effect estimates for binary outcomes using risk ratios (RR) with 95% confidence intervals (CIs). Heterogeneity was evaluated using Cochran's I2 and Q statistics, with a random-effects model applied when I2 exceeded 50%, and a fixed-effects model used otherwise. For randomized trials, the Cochrane Risk of Bias Tool was applied; the Newcastle-Ottawa Scale assessed nonrandomized trials. RESULTS: We analyzed 12 studies involving 4095 patients. The findings showed that vedolizumab had higher clinical remission and response rates compared to adalimumab (RR: 1.24, 95% CI 1.14-1.34, P < 0.01; RR: 1.11, 95% CI 1.01-1.22, P = 0.03). However, no significant differences were observed in endoscopic remission between the two treatments (RR: 0.74, 95% CI 0.47-1.18, P = 0.21). Safety outcomes, based on adverse and serious adverse event rates, have no significant differences (RR: 0.67, 95% CI 0.41-1.12, P = 0.13; RR: 0.78, 95% CI 0.36-1.68, P = 0.53). Treatment persistence also showed no significant difference between vedolizumab and adalimumab (RR: 0.78, 95% CI 0.55-1.12, P = 0.19). CONCLUSIONS: Our study suggests that vedolizumab may be more effective than adalimumab in alleviating symptoms and achieving clinical response. Importantly, this effectiveness is achieved without an increase in adverse events. No significant difference was found in treatment persistence. However, high heterogeneity may weaken the evidence, requiring further randomized trials for confirmation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, 530007, Guangxi, People's Republic of China.
- Department of Gastroenterology, The Fourth Affiliated Hospital of Guangxi Medical University/Liu Zhou Worker's Hospital, No. 156 HePing Road, LiuNan District, Liuzhou, 545005, People's Republic of China.
- Department of General Medicine, Liuzhou People's Hospital, No. 8 WenChang Road, ChengZhong District, Liuzhou, 545001, People's Republic of China.
- Department of Gastroenterology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, 530007, Guangxi, People's Republic of China. huangjiean@gxmu.edu.cn.
Zitieren
APA
Chen, Z., Li, H., Li, Z., Ouyang, R., Huang, S., Qin, S., Qin, J., & Huang, J. (2025). The efficacy, safety, and persistence of vedolizumab versus adalimumab in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01710-4
Vancouver
Chen Z, Li H, Li Z, Ouyang R, Huang S, Qin S, et al. The efficacy, safety, and persistence of vedolizumab versus adalimumab in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01710-4
BibTeX
@article{Chen2025,
author = {Chen, Zhixin and Li, Huo and Li, Zhongzhuan and Ouyang, Rong and Huang, Shijiang and Qin, Shufen and Qin, Jing and Huang, Jiean},
title = {The efficacy, safety, and persistence of vedolizumab versus adalimumab in patients with inflammatory bowel disease: a systematic review and meta-analysis},
journal = {Inflammopharmacology},
year = {2025},
doi = {10.1007/s10787-025-01710-4}
}
EUVIMED